DGAP-News: Bristol Myers Squibb exercises option to extend targeted protein degradation partnership with Evotec

b'The issuer is solely responsible for the content of this announcement.\nEvotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation.